TRAIL in cancer therapy: present and future challenges. - Archive ouverte HAL Access content directly
Journal Articles Expert Opin Ther Targets Year : 2007

TRAIL in cancer therapy: present and future challenges.

(1) , (1) , (1) , (1) , (1)
1

Abstract

Since its identification in 1995, TNF-related apoptosis-inducing ligand (TRAIL) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. In contrast to other members of the TNF superfamily, TRAIL administration in vivo is safe. The relative absence of toxic side effects of this naturally occurring cytokine, in addition to its antitumoural properties, has led to its preclinical evaluation. However, despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity or efficiency. An appropriate understanding of its physiological relevance, and of the mechanisms controlling cancer cells escape from TRAIL-induced cell death, will be required to optimally use the cytokine in clinics. The present review focuses on recent advances in the understanding of TRAIL signal transduction and discusses the existing and future challenges of TRAIL-based cancer therapy development.
Fichier principal
Vignette du fichier
Review_Merino_TRAIL_EOTT_2007.pdf (254.51 Ko) Télécharger le fichier
Vignette du fichier
Figure_1.pdf (180.11 Ko) Télécharger le fichier
Vignette du fichier
inserm-00527108_edited.pdf (313.86 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00527108 , version 1 (18-10-2010)

Identifiers

Cite

Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, Eric Solary, Olivier Micheau. TRAIL in cancer therapy: present and future challenges.. Expert Opin Ther Targets, 2007, 11 (10), pp.1299-314. ⟨10.1517/14728222.11.10.1299⟩. ⟨inserm-00527108⟩
124 View
821 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More